The pharmacological bases of the antiangiogenic activity of paclitaxel.

The pharmacological bases of the antiangiogenic activity of paclitaxel.
复制标题

DOI:
10.1007/s10456-013-9334-0
复制
发表时间:
2013-07
期刊:
影响因子:
9.8
通讯作者:
Danesi, Romano
Danesi, Romano
中科院分区:
医学1区
文献类型:
--
作者:
Bocci, Guido;Di Paolo, Antonello;Danesi, Romano

文献摘要

参考文献

被引文献

相似文献

在20世纪90年代中期,研究人员开始研究紫杉醇的抗血管生成活性,作为促进其体内血管生成活性的可能额外机制。在过去的十年中,许多研究表明,紫杉醇具有抗血管生成活性,这可能归因于抑制小管形成或细胞迁移,以及对活化的内皮细胞的抗增殖作用。此外,紫杉醇显示下调肿瘤细胞中VEGF和Ang-1的表达,并增加肿瘤微环境中TSP-1的分泌。此外,紫杉醇的新药物制剂(如脂质体包封的紫杉醇、ABI-007和包埋在乳化蜡纳米颗粒中的紫杉醇)增强了药物的体内抗血管生成活性。因此,紫杉醇的临床前数据可能被利用来实施一种新的和合理的治疗策略,以控制患者的肿瘤进展。
In the mid 1990s, researchers began to investigate the antiangiogenic activity of paclitaxel as a possible additional mechanism contributing to its antineoplastic activity in vivo. In the last decade, a number of studies showed that paclitaxel has antiangiogenic activity that could be ascribed to the inhibition of either tubule formation or cell migration, and to an antiproliferative effect towards activated endothelial cells. Furthermore, paclitaxel was shown to downregulate VEGF and Ang-1 expression in tumor cells, and to increase the secretion of TSP-1 in the tumor microenvironment. Moreover, the new pharmaceutical formulations of paclitaxel (such as liposome-encapsulated paclitaxel, ABI-007, and paclitaxel entrapped in emulsifying wax nanoparticles) enhanced the in vivo antiangiogenic activity of the drug. Thus, the preclinical data of paclitaxel may be exploited to implement a novel and rational therapeutic strategy to control tumor progression in patients.
DOI: 10.1002/ijc.10907
发表时间: 2003-03-10
影响因子: 6.4
作者:
Grant, DS;Williams, TL;Dicker, AP
通讯作者: Dicker, AP
DOI: 10.3892/or_00000440
发表时间: 2009-08-01
期刊: ONCOLOGY REPORTS
影响因子: 4.2
作者:
Bode, Christian;Trojan, Lutz;Michel, Maurice Stephan
通讯作者: Michel, Maurice Stephan
DOI: 10.1158/1535-7163.mct-06-0242
发表时间: 2006-09-01
影响因子: 5.7
作者:
Bijman, Marcel N. A.;van Nieuw Amerongen, Geerten P.;Boven, Epie
通讯作者: Boven, Epie
DOI: 10.1007/s00280-005-0163-8
发表时间: 2006-09-01
影响因子: 3
作者:
Damber, JE;Vallbo, C;Norrby, K
通讯作者: Norrby, K
DOI: 10.1097/00000421-200306000-00029
发表时间: 2003-06-01
期刊: American journal of clinical oncology
影响因子: --
作者:
Dicker, Adam P;Williams, Torian L;Grant, Derrick S
通讯作者: Grant, Derrick S